TrialArthritis & rheumatology (Hoboken, N.J.)2015

Effect of certolizumab pegol over ninety-six weeks in patients with axial spondyloarthritis: results from a phase III randomized trial.

J Sieper et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.